US Patent

US12410195 — Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders

Formulation · Assigned to Intra Cellular Therapies Inc · Expires 2040-12-10 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions containing the compound of Formula I, including its free base or pharmaceutically acceptable salt form.

USPTO Abstract

The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D 2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Drugs covered by this patent

Patent Metadata

Patent number
US12410195
Jurisdiction
US
Classification
Formulation
Expires
2040-12-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.